A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia
Post-vaccination Surveillance for Monitoring the Adverse Events Following Immunisation With QDENGA in a Real-world Setting in Malaysia (PRIME-Q)
Takeda
2,000 participants
Sep 26, 2024
OBSERVATIONAL
Conditions
Summary
The main aim of this study is to collect the number and type of medical problems (adverse events) after vaccination with QDENGA in Malaysia and to learn more about such medical problems after vaccination. Another aim of this study is to collect the number of persons vaccinated with QDENGA who need to stay in the hospital because of severe dengue fever. No vaccination will be given as part of this study. The study will only collect data of persons already vaccinated with QDENGA who agree to participate.
Eligibility
Inclusion Criteria2
- Participants who have received at least one dose of QDENGA vaccine in Malaysia during the study period.
- Participants or their legally authorized representative (LARs) with a functioning phone number.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This is a non-interventional study.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06388785